10times
23 Jun 2021Ended

Development of a Predictive Spatial Proteomic Signature for the Progression of Ductal Carcinoma In Situ

AboutSpeakersExhibitorsReviewsPhotos

Estimated Turnout

100 - 500
Delegates
Based on previous editions

Editions

Jun 2021

Frequency

Not Available
Claim event to edit details

Ductal carcinoma in situ (DCIS) is a pre-invasive lesion that is thought to be a precursor to invasive breast cancer (IBC). DCIS comprises .. Read more approximately 20% of newly diagnosed breast cancer cases, and unlike IBC is not life-threatening. However, if left untreated, up to half of DCIS patients will develop IBC within 10 years, so clinical management has trended towards presuming all patients are progressors and treating them with surgery, radiation therapy, and pharmacological interventions. Thus, understanding the central biological features in DCIS that drive the transition to IBC is a critical unmet need for guiding appropriate patient care.

  • Followers
  • [ Users who have shown interest for this Event ]
Heidi Schmelzer

Heidi Schmelzer

Research Associate at Abcam

Piedmont, United States
  • Share your Experience
  • Organizer
Logo Follow Company

GenomeWeb

USA115 Total Events

You have no contacts. Please add contacts from below or share on social media

Send to all
No Results